The Science
Too much, too little: what α-MSH does when the dial is stuck
You can see what a signal is for by watching bodies where it is stuck. No peptide for sale is required. α-MSH and the family it belongs to already run, in public, at both ends of their range — too much upstream, and none at all. Both ends are diseases. That is the lesson.
Too much: the skin darkens when the precursor will not stop
α-MSH is one fragment of a larger protein, POMC. Another fragment is ACTH, the pituitary hormone that tells the adrenal to make cortisol.
In primary adrenal insufficiency — Addison’s disease — the adrenal does not answer. Cortisol stays low, feedback fails, and the pituitary keeps releasing ACTH. ACTH is itself a melanocortin peptide. At the concentrations this disease produces, it activates MC1R, the same pigment receptor α-MSH uses. Skin darkens: creases, scars, gums, sun-exposed skin, sometimes a new photograph that no longer matches the old one. Physicians have used that darkening as a clue for generations. It is not a tan anyone ordered. It is melanocortin drive, unopposed, writing itself on the skin.
The point for this site is narrow and worth being narrow about. Pigment can be produced in a person by a melanocortin signal alone, without a week at the beach. That is what the peptide market borrows when it says a vial is “just turning on what the body already does.” Addison’s is the existence proof of the mechanism and, in the same breath, the warning: the high state is an illness. The darkening is not a benefit to be copied. Treating the adrenal failure is a medical problem this page does not advise on.
Too little: red hair, pale skin, and a receptor with nothing to read
Run the same axis the other way. Some children are born unable to make POMC at all. The mutation, first described in people by Krude and colleagues in 1998, removes the precursor, so the fragments never appear: no ACTH for the adrenal, no α-MSH for the pigment receptor, no melanocortin signal at the hypothalamic receptor that restrains appetite.
The picture that follows is the cluster this site already describes, failing from the source rather than from a broken lock. Red hair. Pale skin that does not tan. Adrenal crisis if it is not recognised. Early, severe obesity. MC1R variants produce a similar pigment story by building a receptor that answers poorly; POMC deficiency produces it by never sending the message. Same axis, opposite fault. The genetics are laid out further in why the tanning response is not universal.
That missing message is also why an MC4R agonist, setmelanotide (Imcivree), exists as a prescription drug for a handful of ultra-rare genetic obesities, POMC deficiency among them. The approved drug is named on the wellness-menu piece, which is where its indication and its limits live. It is not a tanning product, and a disease in which the signal is absent is not evidence that healthy people need more of it.
The brake that was part of the design
An accelerator with no brake is not how this system is built.
The endogenous antagonist at MC1R is agouti signalling protein, ASIP. In the mouse, switching agouti on across the hair cycle bands the pigment from black eumelanin to yellow pheomelanin — the same fork the redhead gene forces by weakening the receptor. In people, ASIP is expressed in skin and is part of how the melanocyte is told to stop. Lu and colleagues showed in 1994 that agouti protein antagonises the melanocyte-stimulating hormone receptor: it occupies the lock so the hormone cannot. The dial has two hands.
A gray-market compound built to be more agonist for longer throws that pair away. It has no brake of its own, it resists the enzymes that were the off-switch, and it does not stay local. The potency page separates the three levers that produce that relentlessness. This page adds the human evidence that relentlessness was never the setpoint. The body can darken skin with a melanocortin signal. It can fail to darken skin when the signal is missing. What it does not do, in health, is leave the accelerator down.
Physiology only. Nothing here is a treatment, a dose, or a reason to seek either end of the dial.
Common questions
Why does Addison’s disease darken the skin?
In primary adrenal insufficiency the adrenal no longer makes enough cortisol, so the pituitary keeps releasing ACTH. ACTH is cut from the same precursor as α-MSH and can activate the pigment receptor MC1R. The darkening is melanocortin drive with no drug involved — and it is a disease, not a cosmetic result.
What happens when the body cannot make α-MSH?
People born with POMC deficiency cannot make the precursor that yields α-MSH and several other hormones. The recorded picture includes red hair, pale skin, adrenal failure, and early severe obesity, because MC1R and MC4R are both left without their signal. It is an ultra-rare genetic disease, not a tan that failed.
Does this mean more agonist is better?
No. The high state and the absent state are both illnesses. The system is built with an accelerator and a brake — α-MSH and the endogenous antagonist agouti signalling protein — so the dial can sit in the middle. A compound designed only to push the accelerator harder and longer is the opposite of that design.